EVALUATING ORAL ALENDRONATE SODIUM FOR PREVENTING AND TREATING BONE LOSS

评估口服阿仑膦酸钠预防和治疗骨丢失的作用

• 批准号: 6276676
• 负责人: NANCY L LANE
• 金额: $ 3.28万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276676
• 关键词: alendronate; chemoprevention; clinical research; combination chemotherapy; drug screening /evaluation; glucocorticoids; hormone therapy; human subject; inhibitor /antagonist; oral administration; outcomes research; physiologic bone resorption; skeletal disorder chemotherapy

In this study, investigators are testing the effectiveness and long-term safety of alendronate sodium in preventing glucocorticoid-induced bone loss in men and women on concurrent glucocorticoid therapy.

在这项研究中，研究人员正在测试有效性和长期 丙膦酸钠在防止糖皮质激素诱导的骨的安全性 男性和女性并发糖皮质激素治疗的损失。